

Clinical Policy: Concomitant Antipsychotic Treatment

Reference Number: AZ.CP.PMN.10

Effective Date: 07.16

Last Review Date: 07.20

Line of Business: Arizona Medicaid (AzCH-CCP and Care1st)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Concomitant use of more than one second-generation (atypical) antipsychotic

AHCCCS preferred drugs – multiple—refer to AHCCCS Preferred Drug List.

AHCCCS non-preferred drugs in this class include Abilify MyCite, Seroquel ER (quetiapine ER), Saphris.

FDA approved indications

- Cross tapers will automatically be approved for 60 days at the Point of Sale (POS). Providers must submit a prior authorization request for continued utilization of concomitant use of any 2 atypical antipsychotics beyond the 60 days allowed for cross tapering. This policy includes oral dosage forms in combination with injectable dosage forms of the same agent. (i.e. Abilify and Abilify Maintena; risperidone and Risperdal Consta);
- Prescribers must be contracted behavioral health professionals (BHMP).

Policy/Criteria

Provider *must* submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Provider must provide supporting documentation that adherence to the treatment regimen has not been a contributing factor to the lack of response in the medication trial.

It is the policy of Arizona Complete Health-Complete Care Plan and Care1st that Concomitant is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Refractory Schizophrenia Spectrum Disorder (must meet all):

1. Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder;
2. Prescribed by contracted BHMP;
3. Age \geq 18 years;
 - a. If less than 18, see AZ.CP.PMN.08- Antipsychotic Medications in Children Under 18.

CLINICAL POLICY

Generic Name

4. Evidence of adequate trials of at least three (3) individual antipsychotics listed on the AHCCCS Behavioral Health Drug Lists, for 4-6 weeks at maximum tolerated doses;
5. Failure due to one of the following (a, b, OR c):
 - a. Inadequate response to maximum tolerated dose;
 - b. Adverse reaction(s);
 - c. Documented break through symptoms;
6. Provider must provide supporting documentation that adherence to the treatment regimen has not been a contributing factor to the lack of response in the medication trials.

Approval duration: 6 months

B. Refractory Bipolar Disorder with Psychosis and/or Severe Symptoms (must meet all):

1. Diagnosis of Bipolar Disorder with Psychosis and/or Severe Symptoms;
2. Evidence of adequate trials of at least four (4) evidence based treatment options dependent upon the episode type. Trials may include, but are not limited to combination therapy of antipsychotics and mood stabilizers and/or anticonvulsants. Trials should be 4-6 weeks of maximum tolerated doses, with failure due to:
 - a. Inadequate response to maximum tolerated dose;
 - b. Adverse reaction(s);
 - c. Breakthrough symptoms;
3. Provider must provide supporting documentation that adherence to the treatment regimen has not been a contributing factor to the lack of response in the medication trials.

Approval duration: 6 months

C. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AZ.CP.PMN.53 for Arizona Medicaid.

II. Continued Therapy

A. Refractory Schizophrenia spectrum disorders and refractory bipolar disorder with psychosis and/or severe symptoms (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Documentation of positive response to therapy.

Approval duration: 6 months

B. Refractory Bipolar Disorder with Psychosis and/or Severe Symptoms (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

CLINICAL POLICY

Generic Name

2. Documentation of positive response to therapy

Approval duration: 6 months

C. Other diagnoses/indications (must meet 1 or 2):

1. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – AZ.CP.PMN.53 or evidence of coverage documents

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – AZ.CP.PMN.53 for Arizona Medicaid.
- B. Prescriptions written by **non**-behavioral health professionals.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

BHMP: Behavioral Health Medical Professional

POS: Point of Sale

Appendix B: Therapeutic Alternatives

N/A

Appendix C: Contraindications/Boxed Warnings

See individual Package Inserts.

Appendix D: General Information

N/A

V. Dosage and Administration *

**Only Preferred or formulary atypical antipsychotics listed.*

Drug Name	Indication	Dosing Regimen	Maximum Dose
Aripiprazole (Abilify, Abilify Maintena, Aristada, Abilify MyCite)	Schizophrenia	Adults: 10- 30mg PO/day Adolescents: 2- 30mg/day	30mg/day oral
		Adults: Maintena: 300- 400mg IM/ month	400mg IM/month

CLINICAL POLICY
Generic Name

Drug Name	Indication	Dosing Regimen	Maximum Dose
	Bipolar	<p>Adults: Aristada: 441mg-882mg IM/ 6 weeks 1064mg IM/ 2 months</p> <p>Adults: 15mg- 30mg/day</p> <p>Children- Adolescents: 2- 30mg PO day</p> <p>Maintena: 300- 400mg IM/month</p> <p>Abilify MyCite: 5mg- 30mg daily</p>	<p>882mg IM/month Or 1064mg/IM Q2 months.</p> <p>30mg/day oral 400mgIM/month</p> <p>30mg/day oral</p>
Clozapine (Clozaril, Fazaclo)	Schizophrenia, schizoaffective Bipolar (off label)	<p>Adults: 12.5mg- 450mg/day in divided doses</p> <p>Children & Adolescents: 6.25mg – 300mg/day</p> <p>50-400mg/day</p>	<p>Adults: 900mg/day</p> <p>Children & Adolescents: 300mg/day</p>
Lurasidone (Latuda)	Schizophrenia	<p>Adults: 40- 160mg QD</p> <p>Adolescents: 40-80mg</p>	<p>Adults: 160mg/day</p> <p>Adolescents: 80mg/day</p>

CLINICAL POLICY
Generic Name

Drug Name	Indication	Dosing Regimen	Maximum Dose
	Bipolar depression	QD Adults: 20-120mg QD Children & Adolescents: 20mg-80mg QD	Adults:120mg/day Children & Adolescents: 80mg/day
Olanzapine (Zyprexa, Zyprexa Zydis)	Schizophrenia Bipolar	Adults: 5mg-10mg QD Children & Adolescents: 2.5mg-10mg QD Adults: 10-20mg QD Adolescents: 2.5mg-10mg QD	20mg/day
Paliperidone (Invega Sustenna, Invega Trinza)	Schizophrenia/Schizoaffective disorder	Adults: Sustenna: 39-234 mg IM Q monthly Trinza: 273-819mg IM Q 3 months	Sustenna: 234mg IM every month Trinza: 819mg IM every 3 months.
Quetiapine(Seroquel IR)	Schizophrenia Bipolar	Adults: 25mg-800mg/day Adolescents: 25mg-400mg	Adults and Adolescents: 800mg/day Children > 10 years: 600mg/day

CLINICAL POLICY
Generic Name

Drug Name	Indication	Dosing Regimen	Maximum Dose
		Adults: 50-800mg/day Children & Adolescents: 25mg-600mg/day	
Risperidone (Risperdal, Risperdal Consta, Perseris)	Schizophrenia Bipolar	Adults: 2mg-16mg PO/day Adolescents: 0.5mg-6mg PO/day Consta: Adults: 25mg-50mg IM every 2 weeks Perseris: Adults: 90mg or 120mg SC once monthly Adults: 2-6mg/day PO Children & Adolescents: 0.5mg-6mg/day PO	16mg/day PO Adolescents: 6mg/day PO 50mg Q 2 weeks 120mg Q 4 weeks 6mg/day PO 50mg IM Q2 weeks 6mg/day PO
Ziprasidone (Geodon)	Schizophrenia Bipolar	Adults: 20mg-80mg BID Adults: 40mg-80mg BID	160mg/day

CLINICAL POLICY

Generic Name

VI. Product Availability

Drug Name	Availability
Aripiprazole (Abilify, Abilify Maintena, Aristada, Abilify MyCite)	<p>Tablets: 2mg,5mg,10mg,15mg, 20mg</p> <p>Orally disintegrating tablet: 10mg, 15mg</p> <p>Oral solution: 1mg/ml</p> <p>Powder for suspension for injection: Abilify Maintena: 300mg and 400mg</p> <p>Suspension for Injection: Aristada 441mg/1.6ml; 662mg/2.4ml; 882mg/3.2ml; 1064mg/3.9ml</p> <p>Tablet with sensor: Abilify MyCite 2mg, 5mg, 10mg, 15mg, 20mg, 30mg</p>
Clozapine (Clozaril, Fazaclo)	<p>Orally disintegrating tablet: 12.5mg, 25mg, 100mg, 150mg, 200mg</p> <p>Tablets: 12.5mg, 25mg, 50mg, 100mg, 200mg</p>
Lurasidone(Latuda)	Tablets: 20mg, 40mg, 60mg, 80mg, 120mg
Olanzapine(Zyprexa, Zyprexa Zydis)	<p>Orally disintegrating tablet: 5mg, 10mg, 15mg, 20mg</p> <p>Tablet: 2.5mg, 5mg, 10mg, 15mg, 20mg</p>
Paliperidone(Invega Sustenna, Invega Trinza)	<p>Suspension for injection:</p> <p>Sustenna:39mg/0.25ml; 78mg/0.5ml; 117mg/0.75ml; 156mg/1ml; 234mg/1.5ml</p> <p>Trinza: 273mg, 410mg, 546mg, 819mg</p>
Quetiapine(Seroquel IR)	Tablets: 25mg, 50mg, 100mg, 200mg, 300mg, 400 mg
Risperidone(Risperdal, Risperdal Consta, Perseris)	<p>Orally disintegrating tablets: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg</p> <p>Oral solution: 1mg/ml</p> <p>Tablet: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg</p> <p>Powder for solution for injection (Consta): 12.5mg, 25mg, 37.5mg, 50mg</p>

CLINICAL POLICY

Generic Name

Drug Name	Availability
	Extended-release injectable suspension (Perseris): 90mg, 120mg
Ziprasidone (Geodon)	Capsules: 20mg, 40mg, 60mg, 80mg

VII. References

1. Arizona Complete Health-Complete Care Plan Provider Manual Section 3.8 (Behavioral Health Network provider Service Delivery Requirements-Psychotropic Medication: Prescribing and Monitoring 2020 edition.
2. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. *Schizophrenia Bulletin*, 2009; **35**: 443- 457.
3. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *Am. J. Psychiatry*, 2011; **168**:702-708.
4. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophrenia Research*, 2008; **100**: 20-38.
5. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Converted to new template Added Dosage and Administration; Added Product availability	03.18	07.18
Renamed policy, added new logo and removed Saphris from preferred products; added Abilify MyCite; added Perseris.	07.19	07.19
Annual review: references reviewed and updated; policy formatted.	07.20	07.20
Added Care1st logo. Added verbiage to specify that criteria also applies to Care1st.	5.10.21	04.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

CLINICAL POLICY

Generic Name

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

CLINICAL POLICY

Generic Name

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.